LobbyingNational Community Pharmacists Association lobbying by quarter
National Community Pharmacists Association's latest lobbying report covers Q2 2026, at $290K. The four quarters Q4 2025–Q3 2026 total $840K. Its first report covers Q4 2022; the issues it reports most are Pharmacy and Alcohol & Drug Abuse.
National Community Pharmacists Association
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $840K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $320K | 1 |
| Q1 2023 | $370K | 1 |
| Q2 2023 | $380K | 1 |
| Q3 2023 | $360K | 1 |
| Q4 2023 | $330K | 1 |
| Q1 2024 | $320K | 1 |
| Q2 2024 | $340K | 1 |
| Q3 2024 | $380K | 1 |
| Q4 2024 | $412K | 1 |
| Q1 2025 | $340K | 1 |
| Q2 2025 | $350K | 1 |
| Q3 2025 | $340K | 1 |
| Q4 2025 | $230K | 1 |
| Q1 2026 | $320K | 1 |
| Q2 2026 | $290K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$625.6K · 16 reports
- Alcohol and drug abuse$605.6K · 15 reports
- Defense$605.6K · 15 reports
- Labor, antitrust and workplace$605.6K · 15 reports
- Medicare and Medicaid$605.6K · 15 reports
- Taxation$605.6K · 15 reports
- Budget and appropriations$559.9K · 14 reports
- Telecommunications$320.8K · 9 reports
- Small business$317K · 9 reports
- Trade$230.8K · 7 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)16 reports
- Health & Human Services, Dept of (HHS)16 reports
- HOUSE OF REPRESENTATIVES16 reports
- SENATE16 reports
- Defense, Dept of (DOD)15 reports
- Drug Enforcement Administration (DEA)15 reports
- Federal Trade Commission (FTC)15 reports
- Internal Revenue Service (IRS)15 reports
- Treasury, Dept of15 reports
- Food & Drug Administration (FDA)14 reports
- White House Office14 reports
- Centers For Disease Control & Prevention (CDC)9 reports
- Small Business Administration (SBA)8 reports
- Justice, Dept of (DOJ)7 reports
- U.S. Customs & Border Protection7 reports
- Commerce, Dept of (DOC)5 reports
- Office of Management & Budget (OMB)5 reports
- Federal Reserve System1 reports
- Health Resources & Services Administration (HRSA)1 reports
- Labor, Dept of (DOL)1 reports
- Occupational Safety & Health Administration (OSHA)1 reports
- Transportation, Dept of (DOT)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseNational Community Pharmacists Association | $5.1M | 15 quarters |
| BGR Government Affairs | $20K | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CHARLIE CHAPMAN | Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committee; LA, House Budget Committee; Staff Asst, House Ways and Means Committee; Intern, House Ways and Means Committee | Q2 2026 |
| CHRIS KELLY | Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. Blackburn | Q2 2026 |
| RAGHAV AGGARWAL | Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior | Q2 2026 |
| KAITLIN KRELL | Legislative Aide, Sen. Cynthia Lummis | Q1 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | BGR Government Affairs | $20K |
| 07/17for Q2 | In-house | $270K |
| 06/30for Q2 | BGR Government Affairs | Under $5,000 |
| 04/20for Q1 | In-house | $320K |
| 01/20for Q4 2025 | In-house | $230K |
| 25/11/06for Q3 2025 | In-house | $340K |
| 25/07/21for Q2 2025 | In-house | $350K |
| 25/04/21for Q1 2025 | In-house | $340K |
| 25/03/11for Q2 2024 | In-house | $340K |
| 25/01/21for Q4 2024 | In-house | $412K |
| 24/10/17for Q3 2024 | In-house | $380K |
| 24/07/22for Q2 2024 | In-house | $340K |
| 24/04/22for Q1 2024 | In-house | $320K |
| 24/01/21for Q4 2023 | In-house | $330K |
| 23/10/11for Q3 2023 | In-house | $360K |
| 23/07/12for Q2 2023 | In-house | $380K |
| 23/04/17for Q1 2023 | In-house | $370K |
| 23/01/13for Q4 2022 | In-house | $320K |